Clinical Trials Directory

Trials / Completed

CompletedNCT03526289

GIP/GLP-1 Co-Activity in Subjects With Overweight and Type 2 Diabetes: Lowering of Food Intake

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
22 (actual)
Sponsor
University Hospital, Gentofte, Copenhagen · Academic / Other
Sex
Male
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

The primary aim of the study is to evaluate how GIP receptor activation influence food intake and mechanisms regulating food intake in obese individuals with type 2 diabetes that are in steady treatment with metformin and a GLP-1 receptor agonist.

Detailed description

The study is designed as a double blinded cross-over study with two study days: One day of GIP infusion (for 5 hours) and one day with placebo (saline) infusion (for 5 hours). The primary endpoint is difference in food intake between the two study days. Food intake is examined as amount of food eaten during an ad libitum meal.

Conditions

Interventions

TypeNameDescription
BIOLOGICALGIP1-42 infusion5-hour GIP1-42 infusion (time point 0-300 minutes)
OTHERSaline5-hour infusion of saline (placebo) (time point 0-300 minutes)

Timeline

Start date
2017-11-08
Primary completion
2018-10-24
Completion
2018-10-24
First posted
2018-05-16
Last updated
2018-12-05

Locations

1 site across 1 country: Denmark

Source: ClinicalTrials.gov record NCT03526289. Inclusion in this directory is not an endorsement.